Neurotic, Stress-related and Somatoform Disorders (F4)

Somatoform Disorders

Somatoform disorders are a group of psychiatric conditions characterized by the presence of physical symptoms that cannot be fully explained by a general medical condition, substance use, or another mental disorder, causing significant distress or functional impairment.

1. Definition and Terminology

Somatoform disorders (now reclassified as Somatic Symptom and Related Disorders in DSM-5) represent a group of psychiatric conditions characterised by the presence of physical (somatic) symptoms that cause significant distress and functional impairment, and which are associated with disproportionate and maladaptive thoughts, feelings, and behaviours related to those symptoms [2].

Let's break the name down from its roots:

  • "Somato-" (Greek: soma = body) → relating to the body
  • "-form" (Latin: forma = shape/appearance) → taking the form of

So "somatoform" literally means "taking the form of a bodily [disease]" — i.e., psychiatric distress manifesting as if it were physical illness.

2. Epidemiology

3. Anatomy and Function: The Neurobiology of Somatization

While there is no single "lesion" in somatoform disorders, understanding the relevant neuroanatomy helps explain why emotional distress can produce genuine physical symptoms.

4. Aetiology and Pathophysiology

The aetiology is best understood through the biopsychosocial model [2]:

4.2 Psychological Factors

This is where the major explanatory models live [2]:

5. Classification

6. Clinical Features

6.1 Somatic Symptom Disorder — Symptoms and Signs

The clinical presentation of somatic symptom disorder involves two domains: the somatic symptoms themselves and the maladaptive psychological/behavioural response [2].

6.3 Conversion (Functional Neurological Symptom) Disorder [2]

6.4 Illness Anxiety Disorder (Previously Hypochondriasis) [2]

6.5 Body Dysmorphic Disorder (BDD) [2]

Note: In DSM-5, BDD has been moved to Obsessive-Compulsive and Related Disorders, but it is discussed here due to historical links to somatoform disorders.

6.6 Suggestive Features from History and Examination [2]

7. Approach to Medically Unexplained Symptoms [2]

Differential Diagnosis of Somatoform Disorders

The differential diagnosis of somatoform (somatic symptom and related) disorders is one of the most nuanced exercises in psychiatry. The reason is simple: these disorders sit at the crossroads of medicine and psychiatry, and the symptom overlap with both organic disease and other psychiatric conditions is enormous. Approaching this systematically is therefore essential.

The cardinal rule before considering any psychiatric differential: you must diligently rule out organic causes before considering a psychiatric diagnosis [2]. Somatoform disorders are never a diagnosis of exclusion by convenience — they are a positive diagnosis made on the basis of specific features (disproportionate distress and maladaptive behaviour), but only after adequate medical evaluation.

References

[2] Senior notes: ryanho-psych.md (Sections 8.4.1, 8.4.2.1, 8.4.2.2, 8.4.2.3 — Approach to MUS, Somatic Symptom Disorder, Illness Anxiety Disorder, Other Related Disorders including factitious disorder and malingering)

Diagnostic Criteria

Diagnosis of somatoform disorders is fundamentally a clinical diagnosis — there is no blood test, imaging study, or biomarker that confirms it. The diagnosis rests on recognising a specific pattern of symptoms AND maladaptive responses, after appropriate exclusion of organic disease. Understanding the diagnostic criteria in both ICD-10 and DSM-5 is essential because they differ significantly in philosophy [2].

A. Somatic Symptom Disorder

This is the "core" diagnosis in the somatoform spectrum. The ICD-10 and DSM-5 criteria differ substantially, and understanding why they differ is just as important as memorising them [2].

B. Illness Anxiety Disorder

Investigation Modalities

Management of Somatoform Disorders

Detailed Treatment Modalities

C. Cognitive Behavioural Therapy (CBT) [2]

CBT is the mainstay formal psychotherapy for somatoform disorders [1][2]. It directly targets the cognitive and behavioural factors that maintain the disorder.

E. Pharmacotherapy [1][2]

Pharmacotherapy in somatoform disorders is adjunctive — it is not the primary treatment but plays an important role, especially when comorbid psychiatric conditions are present [2].

References

[1] Lecture slides: GC 167. I feel very nervous Anxiety disorders.pdf (p36–37, treatment of anxiety disorders, antidepressant classes) [2] Senior notes: ryanho-psych.md (Sections 8.4.1, 8.4.2.1, 8.4.2.2, 8.4.2.3 — management of MUS, somatic symptom disorder, illness anxiety disorder, conversion disorder, other related disorders; Section 3.1.1 antidepressants; Section 3.1.4 benzodiazepines and anxiolytics; Section 3.3 psychotherapy)

Complications of Somatoform Disorders

Complications in somatoform disorders are particularly insidious because they arise not only from the disease itself but — critically and often predominantly — from the healthcare system's response to the patient. Many complications are iatrogenic (Greek: iatros = physician, genic = caused by) — literally "caused by the doctor." Understanding this is essential because it means that how you manage these patients directly determines their complication risk.

The complications can be organised into six domains:

  1. Iatrogenic complications from unnecessary investigations and procedures
  2. Substance use disorders
  3. Psychiatric comorbidity and its consequences
  4. Functional impairment and disability
  5. Impact on the healthcare system
  6. Condition-specific complications

References

[2] Senior notes: ryanho-psych.md (Sections 8.4.2.1, 8.4.2.2, 8.4.2.3 — clinical course and complications of somatic symptom disorder, illness anxiety disorder, conversion disorder, body dysmorphic disorder, factitious disorder)

High Yield Summary

Definition: Somatoform disorders = psychiatric conditions where physical symptoms cause significant distress with disproportionate maladaptive thoughts, feelings, and behaviours. DSM-5 renamed these "Somatic Symptom and Related Disorders."

Key Conceptual Shift (DSM-5): No longer requires symptoms to be "medically unexplained" — focuses on the disproportionate response to symptoms.

Epidemiology: 4–6% general population, 17% primary care. F > M. Onset in adolescence/early adulthood. Lower SES and education.

Aetiology — Biopsychosocial:

  • Biological: Genetics (7–21% heritability), neurobiological alterations in emotion-body schema processing
  • Psychological: Amplifying perceptual style, illness-related beliefs, alexithymia, psychodynamic conversion
  • Social: Childhood adversity/abuse, low SES, cultural suppression of emotional expression (highly relevant in Hong Kong)

Classification (DSM-5):

  • Somatic Symptom Disorder (SSD): ≥1 distressing somatic symptom + disproportionate response (≥6 months)
  • Illness Anxiety Disorder (IAD): Preoccupation with serious illness, minimal/no somatic symptoms
  • Functional Neurological Symptom Disorder (FND): Neurological symptoms incompatible with recognised disease
  • Body Dysmorphic Disorder: Now under OCD-related disorders

Key Clinical Features:

  • Multiple somatic symptoms across systems (pain, GI, CVS, neuro, urogenital)
  • Disproportionate worry, checking behaviours, doctor-shopping
  • Negative workups do NOT reassure
  • Comorbid anxiety/depression in 30–60%

Critical Distinctions:

  • Somatoform = unconscious/unconscious/psychological distress
  • Factitious = unconscious/conscious/sick role
  • Malingering = conscious/deliberate/external gain

Course: Chronic, fluctuating. 50–75% improve, rarely fully resolve. Complications: iatrogenic harm from unnecessary procedures, substance use disorders.

Investigation Principle: Be judicious — too many investigations reinforce illness behaviour and risk iatrogenic harm.

High Yield Summary — Differential Diagnosis

Step 1: Always exclude organic disease first — SLE, MS, hyperparathyroidism, thyroid disorders, occult malignancy, HIV, chronic infections, phaeochromocytoma.

Step 2: Distinguish unconscious vs conscious symptom production — somatoform (unconscious/unconscious) vs factitious (unconscious motivation/conscious fabrication) vs malingering (conscious/conscious, external gain).

Step 3: Within the somatoform spectrum — differentiate by (a) whether symptoms are neurological (FND), (b) whether symptoms are minimal with preoccupation about having disease (IAD), (c) whether concern is about appearance (BDD), or (d) whether there is disproportionate response to prominent somatic symptoms (SSD).

Step 4: Distinguish from other psychiatric disorders — Depression (symptoms remit outside episodes), GAD (anxiety pervasive beyond health), Panic disorder (episodic, anticipatory anxiety about attacks), OCD (intrusive, ego-dystonic thoughts with ritualistic compulsions), Delusional disorder (fixed, unshakeable beliefs at delusional intensity), PTSD (trauma exposure required), Adjustment disorder (identifiable stressor, self-limiting).

Key DSM-5 principle: The presence of organic disease does NOT exclude SSD. The absence of organic disease does NOT alone qualify for SSD. The diagnosis is about the disproportionate response.

High Yield Summary — Diagnosis

Somatic Symptom Disorder (DSM-5):

  • Criterion A: ≥1 distressing somatic symptom (medically explained or not)
  • Criterion B: Disproportionate thoughts (catastrophising), anxiety about health, OR excessive time/energy devoted to symptoms — at least ONE required
  • Criterion C: Persistent state of being symptomatic, typically > 6 months
  • Key difference from ICD-10: DSM-5 does NOT require symptoms to be medically unexplained; ICD-10 requires ≥2 years + no physical explanation + refusal of reassurance

Illness Anxiety Disorder (DSM-5):

  • Preoccupation with having/acquiring serious illness + minimal/no somatic symptoms + ≥6 months
  • Two subtypes: care-seeking vs care-avoidant
  • If prominent somatic symptoms present → SSD, not IAD

Functional Neurological Symptom Disorder (DSM-5):

  • Neurological symptoms with clinical evidence of INCOMPATIBILITY with recognised disease
  • Requires POSITIVE signs (Hoover's, entrainment, non-anatomical sensory loss) — NOT just normal investigations
  • No longer requires identified psychological stressor

Investigation Principles:

  • Judicious and targeted, not exhaustive
  • Each test must answer a specific clinical question
  • False positives are dangerous — may trigger iatrogenic cascade
  • Normal results do NOT reassure somatoform patients
  • Review old records before repeating investigations

High Yield Summary — Management

Foundation (ALL somatoform disorders):

  • Therapeutic relationship is the treatment
  • Emphasise symptoms are real; explain psychosocial factors; offer biopsychosocial explanation
  • Scheduled appointments, single clinician, limit investigations
  • Treat comorbid depression/anxiety (SSRI + CBT)

Psychotherapy:

  • CBT is first-line formal psychotherapy for all somatoform subtypes
  • Targets: dysfunctional health beliefs (cognitive restructuring), maladaptive behaviours (ERP/behavioural experiments), psychoeducation (attention-amplification model)
  • 70–90% decline psychotherapy — engagement is the biggest barrier
  • MBCT is second-line, especially for IAD

Pharmacotherapy:

  • SSRIs first-line (start low, go slow — amplifying perceptual style makes patients hypersensitive to side effects)
  • SNRIs useful for pain-predominant presentations (duloxetine for fibromyalgia/chronic pain)
  • Low-dose TCAs (amitriptyline) for chronic pain and insomnia
  • BZDs: SHORT-TERM only (max 1 month), high risk of dependence — avoid in somatoform disorders
  • Propranolol for peripheral autonomic symptoms only

FND-specific:

  • Psychoeducation (1st line) → Physiotherapy for motor / CBT for other symptoms (2nd line)
  • Do NOT reinforce symptoms with wheelchair/mobility aids

Key Pitfalls:

  • Never tell patients "it's all in your head"
  • Never prescribe long-term benzodiazepines or opioids
  • Never order investigations to "reassure" — it doesn't work
  • Never provide mobility aids without active rehabilitation plan for FND

High Yield Summary — Complications

Iatrogenic complications (most important and most preventable):

  • False positives and incidental findings trigger invasive cascade
  • Unnecessary surgeries (exploratory laparotomy, hysterectomy, cholecystectomy) → post-operative pain, adhesions, NO symptom relief
  • Cumulative radiation from repeated CTs
  • Prevention: judicious investigation, single primary clinician, scheduled appointments

Substance use disorders [2]:

  • Narcotic analgesics and benzodiazepines are the main culprits
  • Mechanism: rapid relief → tolerance → dose escalation → dependence → withdrawal symptoms mimic original complaints
  • Prevention: avoid opioids and long-term BZDs in somatoform patients

Psychiatric comorbidity:

  • Depression (30–60%), GAD (71% in IAD), panic (36% in FND), dissociation (47% in FND), personality disorders (77% in IAD)
  • Suicide risk especially in BDD (80% ideation, 25% attempt)

Functional impairment:

  • Occupational disability, social isolation, relationship breakdown, physical deconditioning
  • Deconditioning creates genuine physical symptoms → self-perpetuating cycle

Diagnostic overshadowing:

  • Once labelled, new organic disease may be missed
  • Every new symptom deserves fresh clinical evaluation

Negative prognostic factors: older age, more complaints, comorbid depression/anxiety, maladaptive personality traits (harm avoidance, low cooperativeness) [2]

On this page

No Headings